Newsroom

How the Next Generation Antibody Drug Conjugates...

Antibody-drug Conjugates or ADCs combine the selectivity of antibodies with the efficacy of small molecule drugs, allowing for more precise, targeted, therapeutic applications.Combining the advantages of antibodies in binding a specific target with the capabilities of a therapeutic payload, the majority of ADCs in preclinical and clinical development are for indications in oncology and hematology, where the cytotoxic payloads linked to...

Update COVID-19: MabPlex is here for your...

As COVID-19 continues to have a significant impact on global supply chains and manufacturing, we want to share an update on what MabPlex is doing to keep our employees and customers safe as we continue to deliver world-class CDMO services for biologics.MabPlex is following the guidance of global health experts at the World Health Organization (WHO) and the U.S....

MabPlex successfully hosted the Biopharmaceutical CMC Summit...

On November 8, 2019, Biopharmaceutical CMC Summit was successfully held in Yantai, China, which is also the fourth high-level biomedical summits hosted by MabPlex.

MabPlex Congratulates Encure Biopharma with FDA IND...

MabPlex International Ltd. confirms securing United States Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for Encure Biopharma Co., Ltd.’s (Beijing) YH001 Project. Following this successful FDA IND Clearance, MabPlex will also submit an IND for YH001 to the Chinese National Medical Products Administration (NMPA). This FDA IND Clearance is MabPlex's 3rd Successful IND application...

Introduction to MabPlex San Diego, Shanghai, and...

MabPlex provides global CDMO services in the development and manufacturing of biopharmaceuticals, including mAbs, recombinant proteins, ADCs and bispecifics. We offer our partners contract services from DNA to finished drug product. At our US and Shanghia R&D sites and our manufacturing site in Yantai, China, MabPlex delivers truly integrated solution to our partners.